Renal MRI Biomarkers: The Route to Clinical Adoption

项目总结/摘要 功能性肾MRI生物标志物在研究和临床实践中未得到充分利用，因为需要 内部专业知识和发展。因此，将解决方案转移到其他中心是一个 挑战，导致工作严重重复，方法缺乏标准化， 难以比较各中心的结果。这也限制了商业买入，阻碍了 多中心试验的建立，总体上阻碍了这些生物标志物转化为临床应用。 实践我们提议的研讨会（https：//www.ismrm.org/workshops/2021/Renal/）旨在弥合这一点 间隙这次研讨会的目的是汇集国际公认的科学家和临床医生 与目前正在开发和应用先进的肾脏MRI技术的新研究者一起， 目的是研究肾脏疾病的原因和后果。本次研讨会的议程 整合了概述非侵入性检测和生物标志物需求的临床演示， 介绍了基于对比度的MRI的最新进展，弛豫法的新应用，扩散， 弹性成像、多核应用、临床前动物研究和人工 情报技术以下一代为重点，研讨会将包括 为受训者和新调查员举办的指导课程，称为“与专家见面”。这些指导 会议将提供有关临床试验设计，资金和法规的具体信息，以及 关于可用成像后处理软件的“我是怎么做的”实践课程。这个研讨会是 专为研究人员（包括博士）设计学生和博士后）;临床医生（例如，放射科医生， 肾科医生，肾移植外科医生）; MR技术专家;政府监管专家;非营利组织 和对肾脏疾病早期诊断感兴趣的学术团体;以及ISMRM的成员， 和PARENCHIMA。该计划是专为高级研究人员和初级科学家， 为我们的与会者感兴趣的继续医学教育的相关主题。它展示了 使用定量MRI诊断和监测一系列医疗状况的新方法， 例如，在一个实施例中，肾组织损伤、氧合、造影剂和非造影剂灌注、肾移植前和移植后 我们将提供在临床试验中利用这些知识的方法， 实践，以及数据分析的指导。我们计划的一个关键要素是向妇女伸出援手， 鼓励少数民族参加我们的讲习班。本次研讨会将首次在 北美，但之前由英国肾脏成像共同组织了三次欧洲会议 网络（UKRIN）和COST行动“慢性肾脏病的MRI生物标志物”（PARENCHIMA）。 （https：renalmri.org）. 150多名与会者参加了前几次讲习班， 主持人因此，我们预计社区对拟议的研讨会有浓厚的兴趣。

Project Summary/ Abstract Functional renal MRI biomarkers are underused in research and clinical practice due to the need for dedicated in-house expertise and development. Transferring solutions to other centers is therefore a challenge, leading to a significant duplication of efforts, a lack of standardization in the methods, and difficulties in comparing results between centers. This also limits commercial buy-in, hinders the establishment of multi-center trials, and overall impedes the translation of these biomarkers into clinical practice. Our proposed workshop (https://www.ismrm.org/workshops/2021/Renal/) aims to bridge this gap. The purpose of this workshop is to bring together internationally recognized scientists and clinicians with new investigators who are currently developing and applying advanced renal MRI techniques in order to investigate the causes and consequences of kidney disease. The program of this workshop integrates clinical presentations outlining the needs for non-invasive testing and biomarkers with presentations on recent advances in contrast-based MRI, new applications of relaxometry, diffusion, and elastography, multinuclear applications, pre-clinical animal studies, and application of artificial intelligence techniques. With an important focus on the next generation, the workshop will include mentoring sessions for trainees and new investigators, called “Meet the Experts.” These mentoring sessions will provide specific information on clinical trials design, funding and regulations, as well as a hands-on “how I do it” sessions on available imaging post-processing software. This workshop is designed for researchers (including Ph.D. students and postdocs); clinicians (e.g., radiologists, nephrologists, renal transplant surgeons); MR technologists; government regulatory experts; nonprofit and academic groups interested in early diagnosis of renal disease; as well as members of the ISMRM, ASN, and PARENCHIMA. The program is designed for both senior investigators and junior scientists, with relevant topics for our attendees interested in continuing medical education. It presents knowledge of new methodologies in using quantitative MRI to diagnose and monitor a range of medical conditions, e.g., renal tissue injury, oxygenation, contrast and non-contrast perfusion, renal pre-transplant and post- transplant evaluations, etc. We will provide methods for utilizing this knowledge in clinical trials and practice, as well as guidance on data analysis. A key element of our plan is to reach out to women and minorities to encourage them to attend and participate in our workshop. This workshop will be a first in North America but follows three previous European meetings co-organized by the UK Renal Imaging Network (UKRIN) and the COST action “MRI Biomarkers for Chronic Kidney Disease” (PARENCHIMA). (https://renalmri.org). These previous workshops were attended by over 150 participants and presenters. Thus, we expect robust interest in the community for the proposed workshop.